Gurmit Singh, PA
Physician Assistant · Bakersfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 26 years
- Graduated 2000
Offices
1 location · Ravi Patel M D Inc · 18 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Gurmit Singh’s office at (661) 322-2206 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$99,880
Medicare paid this office $99,880 for 438 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 384 | $70,791 | $80 |
| Long return visit (40+ min) | 92 | $16,367 | $114 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 194 | $4,635 | $11 |
| Short return visit (20+ min) | 38 | $4,202 | $60 |
| Short return visit | 17 | $3,885 | $36 |
Who their Medicare patients are
438 Original Medicare patients in 2024. Average age 71 · Under 65 17% · 85 and older 8% · Women 55% · Also on Medicaid 40% · Health risk score 2.32. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Cancer 52% · Diabetes 40% · Coronary heart disease 37% · Chronic kidney disease 29% · COPD 22% · Atrial fibrillation 18% · Depression 18% · Heart failure 17% · Stroke 9% · Dementia 4%.
The office billed $502,989, Medicare allowed $137,551 and paid $99,880; for 1,622 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 438 | 1,622 | 71 | 2.32 | $502,989 | $99,880 |
| 2023 | 465 | 1,361 | 71 | 2.09 | $540,467 | $111,008 |
| 2022 | 314 | 1,507 | 71 | 2.34 | $573,058 | $121,747 |
| 2021 | 435 | 1,636 | 71 | 2.45 | $433,476 | $121,172 |
| 2020 | 424 | 1,725 | 70 | 2.61 | $364,290 | $107,587 |
| 2019 | 465 | 1,979 | 71 | 2.70 | $419,859 | $123,710 |
| 2018 | 419 | 1,407 | 70 | 2.89 | $329,674 | $93,691 |
| 2017 | 508 | 1,857 | 71 | 2.75 | $422,511 | $121,217 |
| 2016 | 585 | 2,154 | 72 | 2.43 | $457,814 | $131,453 |
| 2015 | 570 | 2,338 | 71 | 2.61 | $458,627 | $131,580 |
| 2014 | 624 | 2,715 | 71 | 2.41 | $581,770 | $164,946 |
| 2013 | 683 | 4,085 | 71 | 2.26 | $630,894 | $183,283 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 407 | $75,574 | $83 |
| Long return visit (40+ min) | 115 | $26,247 | $123 |
| Short return visit (20+ min) | 17 | $3,415 | $60 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 45 | $2,127 | $24 |
2022: 4 services
| Return visit (30+ min) | 262 | $76,975 | $86 |
| Long return visit (40+ min) | 79 | $25,992 | $127 |
| Short return visit (20+ min) | 67 | $9,403 | $61 |
| Short return visit | 24 | $7,843 | $35 |
2021: 5 services
| Return visit (30+ min) | 352 | $84,823 | $88 |
| Short return visit (20+ min) | 129 | $14,991 | $63 |
| Short return visit | 36 | $11,645 | $38 |
| Long return visit (40+ min) | 42 | $8,490 | $129 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $736 | $13 |
2020: 5 services
| Return visit (30+ min) | 367 | $86,769 | $75 |
| Long return visit (40+ min) | 53 | $10,755 | $98 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 37 | $4,933 | $17 |
| Short return visit | 36 | $3,537 | $24 |
| Short return visit (20+ min) | 25 | $1,418 | $55 |
2019: 5 services
| Return visit (30+ min) | 406 | $86,457 | $73 |
| Short return visit | 49 | $17,311 | $32 |
| Long return visit (40+ min) | 74 | $15,709 | $101 |
| Short return visit (20+ min) | 19 | $1,366 | $47 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $704 | $14 |
2018: 5 services
| Return visit (30+ min) | 348 | $74,483 | $72 |
| Long return visit (40+ min) | 76 | $10,887 | $95 |
| Short return visit | 49 | $3,354 | $29 |
| Short return visit (20+ min) | 33 | $2,935 | $47 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $850 | $13 |
2017: 5 services
| Return visit (30+ min) | 373 | $78,629 | $72 |
| Long return visit (40+ min) | 110 | $18,377 | $99 |
| Short return visit (20+ min) | 132 | $18,039 | $49 |
| Short return visit | 53 | $3,699 | $29 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $948 | $13 |
2016: 6 services
| Return visit (30+ min) | 444 | $76,714 | $72 |
| Short return visit (20+ min) | 194 | $31,521 | $50 |
| Long return visit (40+ min) | 115 | $17,557 | $99 |
| Short return visit | 58 | $4,655 | $28 |
| Blood test, clotting time | 36 | $426 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $283 | $14 |
2015: 5 services
| Return visit (30+ min) | 378 | $73,214 | $74 |
| Short return visit (20+ min) | 226 | $31,278 | $47 |
| Long return visit (40+ min) | 103 | $16,612 | $99 |
| Short return visit | 81 | $9,322 | $30 |
| Blood test, clotting time | 58 | $1,001 | $5 |
2014: 5 services
| Return visit (30+ min) | 377 | $81,496 | $72 |
| Short return visit (20+ min) | 273 | $48,093 | $48 |
| Long return visit (40+ min) | 168 | $29,325 | $97 |
| Short return visit | 65 | $5,560 | $29 |
| Blood test, clotting time | 42 | $458 | $5 |
2013: 7 services
| Return visit (30+ min) | 413 | $77,072 | $72 |
| Short return visit (20+ min) | 271 | $40,416 | $50 |
| Long return visit (40+ min) | 183 | $32,682 | $97 |
| Short return visit | 86 | $12,627 | $30 |
| Blood test, clotting time | 74 | $1,791 | $5 |
| Injection of drug or substance under skin or into muscle | 14 | $1,208 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $1,096 | $52 |
Medicaid work
$137,856 in 2024
Medicaid paid $137,856 for 1,313 billed services this clinician did in 2024, up to 92 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,148 | $115,413 |
| Long return visit (40+ min) | 165 | $22,443 |
| 2024 | 1,313 | 2 | 92 | $137,856 |
| 2023 | 1,542 | 4 | 139 | $74,516 |
| 2022 | 1,393 | 4 | 73 | $66,355 |
| 2021 | 1,531 | 4 | 71 | $60,354 |
| 2020 | 1,320 | 3 | 91 | $54,350 |
| 2019 | 300 | 3 | 16 | $3,747 |
| 2018 | 650 | 2 | 20 | $6,895 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 1,258 | $60,600 |
| Long return visit (40+ min) | 236 | $12,618 |
| Short return visit | 35 | $862 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 13 | $436 |
2022
| Return visit (30+ min) | 873 | $44,905 |
| Long return visit (40+ min) | 217 | $13,307 |
| Short return visit | 271 | $6,729 |
| Short return visit (20+ min) | 32 | $1,415 |
2021
| Return visit (30+ min) | 985 | $42,426 |
| Short return visit (20+ min) | 235 | $9,579 |
| Short return visit | 292 | $7,529 |
| Long return visit (40+ min) | 19 | $820 |
2020
| Return visit (30+ min) | 1,175 | $51,866 |
| OFF/OP EST MAY X REQ PHY/QHP | 122 | $1,620 |
| Short return visit (20+ min) | 23 | $863 |
2019
| Short return visit | 141 | $3,089 |
| PROTHROMBIN TIME | 141 | $495 |
| Return visit (30+ min) | 18 | $163 |
2018
| Short return visit | 257 | $5,517 |
| PROTHROMBIN TIME | 393 | $1,379 |
Drugs they prescribed that Part D paid
$365,923
Pharmacies billed $365,923 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (24 of 587) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
515 generic and 72 brand-name prescriptions · $365,923 in drug cost · 42 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 13 | $12,808 | $985 |
| Ondansetron | 21 | $1,009 | $48 |
| Letrozole | 50 | $666 | $13 |
| Prochlorperazine Maleate | 29 | $364 | $13 |
| Ondansetron Odt | 17 | $316 | $19 |
See all 19 drugs
| Eliquis | 13 | $12,808 | $985 |
| Ondansetron | 21 | $1,009 | $48 |
| Letrozole | 50 | $666 | $13 |
| Prochlorperazine Maleate | 29 | $364 | $13 |
| Ondansetron Odt | 17 | $316 | $19 |
| Potassium Chloride | 32 | $308 | $10 |
| Levothyroxine | 42 | $305 | $7 |
| Methylprednisolone | 22 | $265 | $12 |
| Warfarin | 35 | $237 | $7 |
| Hydrocodone-Acetaminophen | 16 | $236 | $15 |
| Hydroxyurea | 20 | $219 | $11 |
| Acyclovir | 15 | $186 | $12 |
| Alendronate | 44 | $157 | $4 |
| Dexamethasone | 13 | $148 | $11 |
| Allopurinol | 19 | $106 | $6 |
| Prednisone | 16 | $77 | $5 |
| Sulfamethoxazole-Trimethoprim | 15 | $77 | $5 |
| Cephalexin | 12 | $70 | $6 |
| Amoxicillin-Clavulanate Potass | 11 | $41 | $4 |
Year by year
| 2024 | 587 | 156 | 4% (24) | 12% | $365,923 |
| 2023 | 543 | 113 | None | 31% | $1,721,429 |
| 2022 | 449 | 109 | 5% (24) | None | $487,383 |
| 2021 | 462 | 121 | 7% (30) | 14% | $264,410 |
| 2020 | 361 | 98 | None | 17% | $295,070 |
| 2019 | 449 | 134 | 5% (23) | 13% | $56,854 |
| 2018 | 367 | 104 | None | 8% | $48,832 |
| 2017 | 368 | 131 | 5% (19) | 7% | $10,364 |
| 2016 | 266 | 111 | None | 10% | $4,729 |
| 2015 | 202 | 84 | 10% (20) | 9% | $22,097 |
| 2014 | 160 | 77 | None | 16% | $2,886 |
| 2013 | 191 | 96 | 6% (11) | None | $7,269 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Ibrance | 33 | $567,748 | $17,204 |
| Imbruvica | 22 | $389,140 | $17,688 |
| Jakafi | 13 | $244,412 | $18,801 |
| Eliquis | 29 | $21,207 | $731 |
| Xarelto | 17 | $11,488 | $676 |
| Letrozole | 71 | $2,350 | $33 |
| Anastrozole | 22 | $1,149 | $52 |
| Hydroxyurea | 17 | $838 | $49 |
| Bicalutamide | 14 | $544 | $39 |
| Acyclovir | 18 | $441 | $24 |
| Warfarin | 40 | $311 | $8 |
| Levothyroxine | 22 | $306 | $14 |
| Ondansetron | 13 | $256 | $20 |
| Potassium Chloride | 23 | $250 | $11 |
| Prochlorperazine Maleate | 14 | $183 | $13 |
| Alendronate | 31 | $116 | $4 |
2022: 12 drugs
| Enoxaparin | 21 | $2,875 | $137 |
| Warfarin | 68 | $940 | $14 |
| Ondansetron | 37 | $846 | $23 |
| Hydrocodone-Acetaminophen | 20 | $504 | $25 |
| Potassium Chloride | 33 | $481 | $15 |
| Prochlorperazine Maleate | 34 | $429 | $13 |
| Acyclovir | 21 | $334 | $16 |
| Diphenoxylate-Atropine | 11 | $327 | $30 |
| Letrozole | 16 | $251 | $16 |
| Klor-Con 10 | 14 | $173 | $12 |
| Allopurinol | 13 | $74 | $6 |
| Anastrozole | 11 | $55 | $5 |
2021: 11 drugs
| Nivestym | 11 | $11,702 | $1,064 |
| Enoxaparin | 16 | $2,735 | $171 |
| Warfarin | 105 | $1,226 | $12 |
| Prochlorperazine Maleate | 55 | $980 | $18 |
| Ondansetron | 38 | $928 | $24 |
| Hydrocodone-Acetaminophen | 18 | $396 | $22 |
| Acyclovir | 31 | $394 | $13 |
| Potassium Chloride | 27 | $317 | $12 |
| Klor-Con 10 | 17 | $175 | $10 |
| Sulfamethoxazole-Trimethoprim | 18 | $83 | $5 |
| Allopurinol | 12 | $62 | $5 |
2020: 5 drugs
| Warfarin | 98 | $1,078 | $11 |
| Ondansetron | 48 | $961 | $20 |
| Prochlorperazine Maleate | 36 | $549 | $15 |
| Potassium Chloride | 26 | $183 | $7 |
| Acyclovir | 12 | $171 | $14 |
2019: 6 drugs
| Warfarin | 179 | $2,508 | $14 |
| Enoxaparin | 13 | $1,849 | $142 |
| Ondansetron | 51 | $458 | $9 |
| Prochlorperazine Maleate | 38 | $391 | $10 |
| Hydrocodone-Acetaminophen | 11 | $184 | $17 |
| Potassium Chloride | 16 | $109 | $7 |
2018: 5 drugs
| Warfarin | 179 | $3,292 | $18 |
| Enoxaparin | 13 | $2,705 | $208 |
| Ondansetron | 33 | $407 | $12 |
| Prochlorperazine Maleate | 27 | $166 | $6 |
| Pantoprazole | 13 | $82 | $6 |
2017: 6 drugs
| Enoxaparin | 14 | $4,383 | $313 |
| Warfarin | 126 | $2,674 | $21 |
| Ondansetron | 39 | $298 | $8 |
| Hydrocodone-Acetaminophen | 14 | $293 | $21 |
| Prochlorperazine Maleate | 29 | $197 | $7 |
| Potassium Chloride | 15 | $106 | $7 |
2016: 5 drugs
| Warfarin | 79 | $1,188 | $15 |
| Ondansetron | 27 | $251 | $9 |
| Prochlorperazine Maleate | 29 | $232 | $8 |
| Potassium Chloride | 17 | $191 | $11 |
| Famotidine | 13 | $37 | $3 |
2015: 4 drugs
| Warfarin | 82 | $1,212 | $15 |
| Hydrocodone-Acetaminophen | 11 | $187 | $17 |
| Ondansetron | 11 | $180 | $16 |
| Prochlorperazine Maleate | 13 | $170 | $13 |
2014: 1 drug
| Warfarin | 72 | $1,022 | $14 |
2013: 4 drugs
| Warfarin | 42 | $660 | $16 |
| Potassium Chloride | 13 | $151 | $12 |
| Prochlorperazine Maleate | 12 | $66 | $5 |
| Lorazepam | 13 | $61 | $5 |
Money from drug and device companies
$733 in 2025
| 2025 | 12 | 27 | None | $733 |
| 2024 | 10 | 23 | None | $503 |
| 2023 | 6 | 17 | None | $355 |
| 2022 | 3 | 5 | None | $96 |
| 2021 | 2 | 2 | None | $37 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Pluvicto | $201 | 13 payments
|
| Medtronic | Mazor X System | $111 | 1 payment
|
| Stemline Therapeutics | Elzonris | $107 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $99 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $47 | 3 payments
|
| Exelixis | Cabometyx | $39 | 2 payments
|
See all 27 published payments
| Novartis Pharmaceuticals | Meals · 2025-11-20 | Pluvicto | $18 |
| Daiichi Sankyo | Meals · 2025-11-17 | Injectafer | $18 |
| Caris MPI | Meals · 2025-11-13 | Mi Cancer Seek | $32 |
| Incyte | Meals · 2025-11-08 | Jakafi | $20 |
| Novartis Pharmaceuticals | Meals · 2025-10-09 | Pluvicto | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-11 | None | $16 |
| Pfizer | Meals · 2025-09-03 | Padcev | $18 |
| Novartis Pharmaceuticals | Meals · 2025-08-15 | Pluvicto | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-08 | None | $16 |
| Novartis Pharmaceuticals | Meals · 2025-07-30 | Scemblix | $10 |
| Novartis Pharmaceuticals | Meals · 2025-07-23 | Pluvicto | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-01 | None | $15 |
| Exelixis | Meals · 2025-06-26 | Cabometyx | $20 |
| Medtronic | Meals · 2025-05-29 | Mazor X System | $111 |
| Novartis Pharmaceuticals | Meals · 2025-05-27 | Pluvicto | $15 |
| Novartis Pharmaceuticals | Meals · 2025-04-17 | Scemblix | $23 |
| Stemline Therapeutics | Meals · 2025-04-17 | Elzonris | $107 |
| Novartis Pharmaceuticals | Meals · 2025-04-10 | Pluvicto | $15 |
| Novartis Pharmaceuticals | Meals · 2025-04-10 | Pluvicto | $1 |
| Exelixis | Meals · 2025-03-25 | Cabometyx | $20 |
| GlaxoSmithKline | Meals · 2025-03-24 | Ojjaara | $99 |
| Novartis Pharmaceuticals | Meals · 2025-03-03 | Lutathera | $35 |
| Novartis Pharmaceuticals | Meals · 2025-02-12 | Scemblix | $8 |
| BeiGene USA | Meals · 2025-02-12 | Brukinsa | $26 |
| Novartis Pharmaceuticals | Meals · 2025-02-06 | Pluvicto | $12 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-28 | Opdivo | $16 |
| Novartis Pharmaceuticals | Meals · 2025-01-08 | Pluvicto | $16 |
See earlier years (2024, 2023, 2022, 2021)
2024: $503
| Novartis Pharmaceuticals | Pluvicto | $209 | 13 payments
|
| GlaxoSmithKline | Ojjaara | $124 | 1 payment
|
| Daiichi Sankyo | Injectafer | $39 | 2 payments
|
| Lilly USA | Verzenio | $23 | 1 payment
|
| Exelixis | Cabometyx | $22 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $20 | 1 payment
|
| Pfizer | Inlyta | $18 | 1 payment
|
| Janssen Biotech | Darzalex | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $16 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $16 | 1 payment
|
2023: $355
| Novartis Pharmaceuticals | Lutathera | $138 | 9 payments
|
| Medtronic | Intellis Adaptivestim | $88 | 1 payment
|
| Exelixis | Cabometyx | $41 | 2 payments
|
| Astellas Pharma US | Padcev | $34 | 2 payments
|
| BeiGene USA | Brukinsa | $33 | 2 payments
|
| Incyte | Jakafi | $22 | 1 payment
|
2022: $96
| Astellas Pharma US | Padcev | $41 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $37 | 2 payments
|
| Epizyme | Tazverik | $18 | 1 payment
|
2021: $37
| Seagen | Padcev | $19 | 1 payment
|
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1598881286
- Licence
- CA PA15939
- Group
- Ravi Patel M D Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-03-22
- NPI last updated
- 2026-09-17
- NPI record certified
- 2026-09-17
This is when the NPI record was last certified, not a medical board exam.